Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Watanabe

Showing results (761-770 of 817) with videos related to

Pageof 82
Sort By:
Lancet (London, England)|May 15, 2017
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialToyoaki Hida, Hiroshi Nokihara, Masashi Kondo, et al.
Lung Cancer (Amsterdam, Netherlands)|January 31, 2025
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patientsTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Anticancer Research|October 28, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 ExpressionAosa Sasada, Hayato Kawachi, Tadaaki Yamada, et al.
Cancer Research Communications|July 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung CancerTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Translational Lung Cancer Research|June 19, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expressionHayato Kawachi, Tae Hata, Tadaaki Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)|December 9, 2019
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancerKazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 1, 2023
Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancerKyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, et al.
Plos One|August 31, 2017
Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cellsTomohiro Tanaka, Satoshi Watanabe, Miho Takahashi, et al.
Clinical Lung Cancer|January 26, 2025
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort StudyTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Scientific Reports|July 13, 2022
Prospective assessment using <sup>18</sup>F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancerOu Yamaguchi, Kyoichi Kaira, Ichiro Naruse, et al.
Pageof 82

Showing results (761-770 of 817) with videos related to

Sort By:
Pageof 82
Lancet (London, England)|May 15, 2017
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialToyoaki Hida, Hiroshi Nokihara, Masashi Kondo, et al.
Lung Cancer (Amsterdam, Netherlands)|January 31, 2025
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patientsTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Anticancer Research|October 28, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 ExpressionAosa Sasada, Hayato Kawachi, Tadaaki Yamada, et al.
Cancer Research Communications|July 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung CancerTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Translational Lung Cancer Research|June 19, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expressionHayato Kawachi, Tae Hata, Tadaaki Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)|December 9, 2019
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancerKazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 1, 2023
Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancerKyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, et al.
Plos One|August 31, 2017
Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cellsTomohiro Tanaka, Satoshi Watanabe, Miho Takahashi, et al.
Clinical Lung Cancer|January 26, 2025
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort StudyTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Scientific Reports|July 13, 2022
Prospective assessment using <sup>18</sup>F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancerOu Yamaguchi, Kyoichi Kaira, Ichiro Naruse, et al.
Pageof 82